Suma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $301.00 on Friday. Krystal Biotech, Inc. has a 52-week low of $127.99 and a 52-week high of $319.48. The stock has a market cap of $8.87 billion, a price-to-earnings ratio of 40.24 and a beta of 0.53. The firm has a fifty day moving average of $282.39 and a 200-day moving average of $264.19.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 7.83 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Public Sector Pension Investment Board boosted its stake in Krystal Biotech by 15.9% during the 3rd quarter. Public Sector Pension Investment Board now owns 100,431 shares of the company’s stock worth $17,729,000 after acquiring an additional 13,743 shares during the last quarter. SG Americas Securities LLC raised its holdings in Krystal Biotech by 469.9% during the 4th quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock worth $4,662,000 after buying an additional 15,591 shares during the period. William Blair Investment Management LLC lifted its stake in Krystal Biotech by 63.9% in the third quarter. William Blair Investment Management LLC now owns 149,302 shares of the company’s stock valued at $26,356,000 after buying an additional 58,203 shares in the last quarter. WINTON GROUP Ltd bought a new position in Krystal Biotech in the third quarter valued at approximately $1,450,000. Finally, Handelsbanken Fonder AB lifted its stake in Krystal Biotech by 58.4% in the fourth quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock valued at $26,084,000 after buying an additional 39,000 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KRYS. Guggenheim increased their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Wall Street Zen upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Evercore restated an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. HC Wainwright restated a “buy” rating and issued a $310.00 price objective on shares of Krystal Biotech in a research note on Monday, June 1st. Finally, Chardan Capital increased their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Ten investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.